PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

Caroline A. Lee  ¹     Yong Tang     Cassandra Schroeder     Jinkun Zhang     Thai Nguyen-Cleary     Susan Mullin     Michael Ma     Naomi Lyon     John S. Grundy    
¹ Arena Pharmaceuticals, Inc., San Diego, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)